Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

Company profile
Ticker
PBLA
Exchange
Website
CEO
Michael Cullen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Canary Merger Holdings, Inc. • Panbela Therapeutics Pty Ltd ...
PBLA stock data
News
Panbela Announces First Patient Enrolled In Aspire Trial Studying SBP-101 In Combination With Gemcitabine, Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
11 Aug 22
Panbela Expands Aspire Trial To Australia, Studying SBP-101 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
4 Aug 22
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
25 Jul 22
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session
22 Jul 22
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
6 Jul 22
Press releases
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
1 Aug 22
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic
28 Jun 22
Investment data
Securities sold
Number of investors
Calendar
12 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.39M | 7.39M | 7.39M | 7.39M | 7.39M | 7.39M |
Cash burn (monthly) | 1.49M | 59.33K | 1.33M | 1.01M | 1.49M | 768.5K |
Cash used (since last report) | 6.6M | 262.07K | 5.9M | 4.45M | 6.6M | 3.39M |
Cash remaining | 788.49K | 7.12M | 1.49M | 2.94M | 785.55K | 3.99M |
Runway (months of cash) | 0.5 | 120.1 | 1.1 | 2.9 | 0.5 | 5.2 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Sep 21 | Horvath Susan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.26 | 12,135 | 27.43K | 12,135 |
13 Sep 21 | Simpson Jennifer K. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.26 | 19,125 | 43.22K | 19,125 |
25 May 21 | Michael T. Cullen | Common Stock | Grant | Acquire A | No | No | 0 | 4,316 | 0 | 216,811 |
25 May 21 | Michael T. Cullen | Stock Option Common Stock | Grant | Acquire A | No | No | 4.17 | 12,368 | 51.57K | 12,368 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acquisition, Asia, ASPIRE, asset, ASU, back, boast, burden, cadence, colorectal, contemplated, CPP, customary, deteriorate, deterioration, diversification, diversify, entity, Europe, expand, expanded, failure, fall, familial, FAP, FASB, highlighting, Ia, Ib, implement, injected, lack, lead, leading, long, merger, mice, milestone, modulator, neoadjuvant, omicron, opening, ovarian, Pacific, pipeline, post, PR, prolonged, proposed, qualify, ranging, rare, recurrence, removing, retain, retrospective, role, royalty, satisfaction, secure, settlement, shareholder, stage, steady, strategic, Subtopic, sustain, transition, winter, xii, xiii, xiv
Removed:
accredited, Additionally, adenocarcinoma, adverse, agent, aggregate, alternate, arising, ASCO, assessment, attend, attendance, begin, begun, blood, CA, care, cell, chain, checkpoint, closed, collaboration, conducting, continued, detachment, disease, disrupt, ductal, Eleven, emerge, epidemic, estimate, exact, exercisable, expenditure, expired, explore, exploring, funding, generated, globe, grow, half, history, impacting, IND, indefinite, inform, informing, ingredient, insurance, interrupted, invest, investigative, investor, June, justify, laboratory, light, listing, mandated, manufacture, Marker, measured, measuring, mechanism, medical, Medicine, Meeting, mitigation, monotherapy, noted, objective, Oncology, ophthalmologic, order, partial, pause, planned, predicted, prevented, procure, reduction, remotely, requested, responding, restarted, resumed, retinal, retinopathy, scheduled, School, screening, sensitizing, separated, shipment, showed, Society, temporary, treat, UFRF, uncertain, valuation, worsen
Financial reports
Current reports
8-K
Expects interim data by early 2024
11 Aug 22
8-K
Entry into a Material Definitive Agreement
19 Jul 22
8-K
Regulation FD Disclosure
22 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 22
8-K
Panbela Provides Business Update and Reports Q1 2022 Financial Results
12 May 22
8-K
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
24 Mar 22
8-K
Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end
22 Feb 22
8-K
Panbela Provides Business Update and Reports Q3 2021 Financial Results
10 Nov 21
8-K
Panbela Provides Business Update and Reports Q2 2021 Financial Results
11 Aug 21
8-K
Panbela Therapeutics Announces $5.0 Million Bought Deal Offering of Common Stock
2 Jul 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
19 Jul 22
D
Indefinite amount in equity / options, sold $8.8M, 70 investors
29 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 22
S-8
Registration of securities for employees
22 Jun 22
POS AM
Prospectus update (post-effective amendment)
22 Jun 22
POS AM
Prospectus update (post-effective amendment)
22 Jun 22
8-K12B
Notification of registration of securities
16 Jun 22
Other
EFFECT
Notice of effectiveness
27 Jun 22
EFFECT
Notice of effectiveness
27 Jun 22
UPLOAD
Letter from SEC
2 May 22
UPLOAD
Letter from SEC
26 Apr 22
CORRESP
Correspondence with SEC
25 Apr 22
UPLOAD
Letter from SEC
20 Apr 22
EFFECT
Notice of effectiveness
29 Mar 22
EFFECT
Notice of effectiveness
12 May 21
CORRESP
Correspondence with SEC
9 May 21
UPLOAD
Letter from SEC
6 May 21
Ownership
3
Panbela Therapeutics / Jeffrey E. Jacob ownership change
27 Jun 22
3
Panbela Therapeutics / Daniel Donovan ownership change
24 Jun 22
SC 13G/A
Panbela Therapeutics / Cullen Michael T. ownership change
14 Feb 22
4
Panbela Therapeutics / Jennifer K. Simpson ownership change
15 Sep 21
4
Panbela Therapeutics / Susan Horvath ownership change
15 Sep 21
4
Panbela Therapeutics / Suzanne Gagnon ownership change
11 Jun 21
4
Panbela Therapeutics / Arthur Fratamico ownership change
27 May 21
4
Panbela Therapeutics / Donald Robert Schemel ownership change
27 May 21
4
Panbela Therapeutics / JEFFREY S MATHIESEN ownership change
27 May 21
4
Panbela Therapeutics / Paul W. Schaffer ownership change
27 May 21
Patents
Utility
Methods for Producing (6S,15S)-3,8,13,18-TETRAAZAICOSANE-6,15-DIOL
13 Jan 22
The present invention provides methods of synthesizing (6S,15S)-3,8,13,18-tetraazaicosane-6,15-diol and salts thereof.
Utility
Methods for producing (6S,15S)-3,8,13,18-tetraazaicosane-6,15-diol
24 Aug 21
The present invention provides methods of synthesizing (6S,15S)-3,8,13,18-tetraazaicosane-6,15-diol and salts thereof.
Reddit threads
Daily Discussion Thread - August 12th, 2022
12 Aug 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Discussion Thread - March 24th, 2022
24 Mar 22
Daily Discussion Thread - March 23rd, 2022
23 Mar 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22
Daily Discussion Thread - March 21st, 2022
21 Mar 22
Daily Discussion Thread - November 10th, 2021
10 Nov 21
Daily Discussion Thread - November 9th, 2021
9 Nov 21
Daily Discussion Thread - November 8th, 2021
8 Nov 21